AlphaMadera's AlphaVal page computes Kura Oncology, Inc.'s fair value using a multi-method blend (DCF, comparable-multiples, and Graham-style intrinsic value), then compares it to the current market price to flag KURA as undervalued, fairly valued, or overvalued.

What is Kura Oncology, Inc.'s fair value?

Fair value for KURA is a model output combining discounted cash flow projections, peer-group multiples, and a Graham number floor. The live AlphaVal page shows the blended fair value alongside each method's individual estimate.

How does AlphaMadera value KURA?

AlphaVal uses three primary techniques: a five-year discounted-cash-flow projection with terminal multiple, peer-group multiple analysis (P/E, EV/EBITDA, P/S), and Graham's defensive-investor intrinsic-value formula. Inputs come from KURA's most recent reported fundamentals.

KURA - Kura Oncology, Inc.

Price: -- -- | CONSENSUS: Buy DETAILS | PRICE TARGET: $19.33 DETAILS

AlphaVal

Deterministic, archetype-aware fair value

AlphaVal Unavailable

AlphaVal: KURA has had negative net income and negative EPS in all 5 available fiscal year(s). Quality gate: persistently unprofitable companies are excluded.